Saskatchewan Entrepreneurs Launch Addiction Recovery App on iOS and Android
Founded by a team with lived experience in both addiction and recovery, AlchemistOne is now available for download on iOS and Android. The app offers a powerful digital companion for those navigating addiction, anxiety, depression, and the often-overlooked complexity of the mind itself.
Developed in Regina, with operations spanning Saskatchewan and Alberta, AlchemistOne delivers deeply personalized experiences rooted in mindfulness, introspection, and self-inquiry. Its content is curated by mental health professionals and individuals in long-term recovery from around the world, offering profound insight into what it means to struggle, what it means to think, and how freedom can arise from a healthier relationship with our inner world.
"When we're struggling, there can be a prevailing sense that we're broken, or not good enough, or that we don't fit in," said Adam Geiger, Co-Founder and CEO of AlchemistOne. "Freedom comes in discovering that's simply not true."
Key features of AlchemistOne include:
A growing library of personalized audio and video journeys — from guided meditations to raw, honest reflections by recovering addicts, therapists, and philosophers.
In-app workout tracking and integration with wearables.
Integrated Quests that encourage deeper reflection through journaling, gratitude practices, and other self-guided activities.
Coming soon: AlchemistOne's AI-powered support tool, co-designed with people in recovery and mental health professionals.
At the heart of the platform is a lived-experience model that challenges conventional narratives around mental health, offering not just coping strategies, but a reimagined way of relating to ourselves.
"AlchemistOne is built on the real experiences of people who've been there, including myself," said Geiger. "Addiction and depression can feel incredibly isolating and overwhelming. Our goal is to ensure no one has to face it alone, and to provide hope that there really is another way."
With addiction and mental health challenges continuing to rise across Canada and globally, many are turning to new tools and approaches for support.
"Technology alone isn't the answer," said Geiger. "But it can be a powerful ally - especially when it's built by and for people in recovery. We're grateful for the opportunity to offer a possible solution."
About AlchemistOne
AlchemistOne is a mental health and addiction recovery platform designed to help people reframe their relationship with the mind. The app combines evidence-informed tools, community-driven content, and soon, AI-assisted support — all grounded in lived experience — to empower individuals seeking freedom from addiction.
SOURCE AlchemistOne Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
3 hours ago
- Cision Canada
PetPlace Offers Microchipping Advice From Experts in Support of Check the Chip Day on August 15 Français
The microchip awareness day is part of a nationwide campaign to reduce the number of lost pets in the U.S. NEW YORK, Aug. 11, 2025 /CNW/ -- Lost pets are a big problem in the United States. It's estimated that approximately 10 million get lost each year, with 1 in 3 pets expected to go missing during their lifetimes. Unfortunately, many of these pets never find their way home. That's why PetPlace is supporting the American Animal Hospital Association (AAHA) and American Veterinary Medical Association's (AVMA) Check the Chip Day, a national awareness event that encourages pet parents to microchip their pets and register their microchips. "A lost microchipped pet is much more likely to be reunited with their owners than a pet who isn't microchipped," says Dr. Rhiannon Koehler, a PetPlace veterinary expert who works as a medical provider in animal shelters. "Lost dogs are over twice as likely to be returned to their owners if they're microchipped. Over a third of lost microchipped cats are returned to their owners, compared with under 2 percent of lost cats who are not microchipped." The Importance of Microchip Registration Microchips only work if they are properly registered. That's why PetPlace launched its Paws for Safety Awareness campaign earlier this summer. "We refer to pets who are microchipped but not registered as digital strays," says Sam Watson, president of PetPlace. "While they might have a physical microchip, that chip is useless if it's not registered with a pet owner's contact information. Registering your dog or cat's chip is the first step in protecting them if they go missing." Essential Microchip Tips for Keeping Pets Safe Dr. Koehler recommends the following microchip tips: Get your microchip from a licensed veterinarian or reputable microchip service provider. These providers ensure proper chip placement and a sterile environment for the procedure. If cost is a concern, contact nonprofit clinics, animal shelters, and animal control organizations to see if they offer discounted or free microchipping services. Ensure the chip is ISO-compliant and can be read by universal scanners. Your microchip provider should be able to tell you if this is the case. Keep a record of your microchip number in a safe place so that it is easily accessible. Write down the number and store it with other important documents and save a copy digitally on your phone or computer. Register your chip with a reliable registry partner. A microchip registry links your information to your pet's chip. Reputable registries make it easy to enter and update your pet's microchip, ensure secure data storage, and offer around-the-clock lost pet services. Include multiple contacts in your microchip information in case you are unreachable. Including the contact number of another family member or friend can be helpful if your pet goes missing and you lose cell phone service or your battery dies. Regularly update your microchip information. This is especially important if you get a new phone number or move. Consider setting an annual reminder to check your chip information. Ask your veterinarian to scan your pet's microchip at annual appointments so you know it's working properly. Although it's rare, microchips can move or stop working. Your veterinarian can confirm that your pet's microchip is working properly. Consider adding an additional ID tag to your pet's collar as a backup. Physical ID tags provide an extra layer of security if your pet's microchip does stop working. If your pet gets lost, report it immediately. Notify your microchip registry and local shelters. Pet parents can register their microchips at PetPlace and join 24PetWatch, North America's largest microchip registry that has successfully reunited over 760,000 lost pets with their families. "Losing a pet is one of the most scary and stressful things a pet parent can go through, but the relief that comes with reunification is real and palpable," says Watson. "Microchipping your pet and registering that microchip provides peace of mind and ensures that you have all safeguards in place should the unthinkable happen." About PetPlace PetPlace ® is a network of innovative products and services designed to support pet well-being, the pet parenting journey, and animal welfare organizations. PetPlace is committed to creating a world where pet care is easy for all, and every pet thrives in a loving home. PetPlace is owned by Independence Pet Holdings, Inc. (IPH), an organization that manages a diverse and broad portfolio of modern pet health brands offering a range of pet insurance services, pet education, lost pet recovery services, and beyond across the U.S. and Canada.
Cision Canada
3 hours ago
- Cision Canada
/R E P E A T -- Claigan Webinar - Are Canadian Products Safer than Products in Poland?/
For toxins in consumer products OTTAWA, ON, Aug. 5, 2025 /CNW/ - On 13 August 2025, Claigan Environmental Inc. ( will present and compare the findings of restricted materials testing on consumer products from Canada and Poland. Over the last two years, Claigan tested sixty (60) similar consumer products sourced from Canada and Poland for restricted materials. In particular, we focused on DEHP (which causes attention deficit) and lead (a reproductive toxin and carcinogen). This webinar will look at real restricted materials test data concerning products you buy and touch everyday. Whose products do you think have the higher risk? Is it Poland? Or is it Canada? Attend this webinar to find out. The main topics to be covered in this webinar are: Which products are safer? Levels of carcinogens and reproductive toxins Effects of the levels detected % of products tested with harmful levels of chemicals Comparison of product types and level of harm Are the same products found in the US and the rest of the EU? Due to the interest in these topics, two (2) webinars will be held on August 13 to accommodate a larger audience. About Claigan Environmental ( Claigan is the leading provider of restricted materials compliance. Claigan has tested tens of thousands of products for restricted materials compliance and offers complete cost effective solutions for even the most complex products. Claigan is an ISO 17025 certified laboratory and is dedicated to providing practical solutions for supply chain due diligence and social responsibility. At Claigan, we believe in 'Less Journey. More Results.'
Cision Canada
3 hours ago
- Cision Canada
Drugs developed decades ago reduced Canadian mortality rates 49 percent - saving 847,000 life-years by 2022, and reduced hospital utilization by 55 percent - avoiding potential healthcare costs of $78.7 billion in 2022 alone
Lichtenberg study reveals virtuous legacy of pharmaceutical innovation: Canadian Health Policy Institute TORONTO, Aug. 11, 2025 /CNW/ - New research from the world's leading pharmaceutical economist affirms that Canadians continue to receive significant windfall gains from global pharmaceutical innovation that occurred decades ago. Columbia University Professor and affiliate of the U.S. National Bureau of Economic Research, Frank R Lichtenberg, PhD, examined whether the new drugs that were approved by government regulators in earlier years had any impact on Canadian mortality rates or use of hospital services in later years. Using publicly available data spanning from 1970 to 2022, Lichtenberg estimated that if those innovative medicines had not been available in Canada, the number of life-years lost before age 75 would have been 49 percent higher by 2022. Pharmaceutical innovation that occurred in the earlier years saved 847 thousand Canadian life-years. In a separate analysis of hospital utilization, he estimated that without access to the new drugs that were released during 1970-1991, the total number of hospital days used by Canadians would have been 55 percent higher in 2022. Total national spending on hospitals in 2022 was CA$143 billion – almost all of it paid by governments, so lower utilization avoided significant costs for taxpayers. Lichtenberg explained the cost implications, "Pharmaceutical innovation occurring in earlier years saved 14.2 million hospital days that otherwise would have been used. The estimated reduction in 2022 hospital expenditure attributable to drug innovation during 1970-1991 was CA$78.7 billion – twice as large as 2022 national expenditure on all prescribed medicines and related supply chain costs totaling CA$37.4 billion." The data also revealed that new classes of drugs had a more immediate effect on mortality than new drugs, but the former effect was smaller and less statistically significant than the latter effect. For example, new classes of drugs authorized during 1990-2011 were estimated to have reduced the growth in the number of years of life lost before age 65 – 29 percent by 2022, while the corresponding estimate for new drugs authorized during 1978-1999 was 39 percent. The study further found that the age-adjusted mortality rate from a disease in a province and year was statistically significantly inversely related to the number of drugs used to treat the disease that were covered on public drug program formularies in that province 4-12 years earlier. The study was funded by Innovative Medicines Canada, the national industry association of research based pharmaceutical companies. It was published in Canadian Health Policy, the free access journal of the Canadian Health Policy Institute (CHPI) a non-governmental think tank. Brett J Skinner, founder and CEO of the Institute and Editor of the journal said, "Lichtenberg's study is empirical evidence of a virtuous legacy from past investments in the research and development of new medicines." The study is available at – Lichtenberg, F. R. (2025). The impact of pharmaceutical innovation on mortality and hospital utilization in Canada, 2000–2022. Canadian Health Policy, AUG 2025. Media Contact: Frank R Lichtenberg, PhD, Columbia University, National Bureau of Economic Research, and CESifo. [email protected]. Columbia University, Kravis Hall 522, 665 West 130th Street, New York, NY 10027.
